NextCure

NextCure is a clinical-stage biotech focused on discovering and developing first-in-class immunomedicines for cancer and immune-related diseases. Founded on pioneering Yale University research, the company employs its proprietary FIND platform to systematically identify novel immunosuppressive targets beyond the PD-1/CTLA-4 axis. Its strategy targets patient populations unresponsive to existing immunotherapies, with a pipeline led by candidates against Siglec-15 and LAIR-1. The company went public in 2019 and is navigating clinical development with a focus on novel biology.

The Functional, Integrated, NextCure Discovery (FIND) platform is a proprietary system that identifies and characterizes novel cell surface and secreted proteins regulating immune function through high-throughput screening of human immune cell interactions and functional assays.

NextCure competes with large pharma immuno-oncology leaders and numerous biotechs exploring next-generation checkpoints. Its differentiation is the novelty of its targets (e.g., Siglec-15, LAIR-1) discovered via its FIND platform, aiming to avoid direct competition with established pathways. However, it faces the risk of other companies pursuing similar biology or developing more effective therapies for the same patient populations.